International application No.
PCT/US04/237884 —

A. CLASSIFICATION OF SUBJECT MATTER					
IPC(7) : C 07C 69/76, 61/00, 51/16					
US CL : 560/008; 562/400, 405					
According to International Patent Classification (IPC) or to both national classification and IPC B. FIRLDS SEARCHED					
	cumentation searched (classification system followed l	by classification symbols)	Ï		
U.S. : 560/008; 562/400, 405					
Documentation	on searched other than minimum documentation to the	extent that such documents are included i	n the fields searched		
	ta base consulted during the international search (nam	e of data base and, where practicable, sear	rch terms used)		
STN REGISTRY, CAPLUS, WEST, EAST					
	•				
C. DOCT	JMENTS CONSIDERED TO BE RELEVANT				
Category *	Citation of document, with indication, where a	ppropriate, of the relevant passages	Relevant to claim No.		
X	CA 2002:487541 (BESWICK et al) 27 June 2002 (2)		1 in part, 3 in part, 22		
	•	,,	in part, 24 in part, 46		
			in part.		
х	CA 2002:964313 (BROOKS et al) 19 December 200	2 (19.12.2002), see the entire abstract.	1 in part, 3 in part, 22		
			in part, 24 in part, 44		
		•	in part, 46 in part.		
x	CA 1999:184126, (TAJIMA et al) 11 March 1999 (1	1 03 1000) see the entire obtanct :	1 in part, 3 in part, 10-		
^	CA 1999.104120, (IAMINIA et al) 11 Maich 1999 (I	1.03.1999), see the entire abreact	11 in part, 14-19 in		
			part, 22 in part, 24 in		
			part, 31-32 in part, 35-		
			40 in part, 44 in part,		
			46 in part, 53-54 in		
			part, 57-62 in part		
!	•				
፟ .					
Further	documents are listed in the continuation of Box C.	See patent family annex.			
• 8	pecial estegmies of cited documents:	"T" later document published after the inter- and not in conflict with the application b	national filing date or priority date		
"A" document	defining the general state of the set which is not considered to be of	principle or theory underlying the invent			
particular relevance "X" document of particular relevance; the claimed invention cannot be					
"B" earlier app	plication or patent published on or after the international filing date	considered novel or cannot be considere			
"L" document	which may throw doubts on priority claim(s) or which is cited to	when the document is taken alone			
	the publication date of mother citation or other special reason (as	"Y" document of particular relevance; the cle			
specified)		considered to involve an inventive step with one or more other such documents,			
"O" document	referring to an oral disclosure, use, exhibition or other means	to a person skilled in the art	swer currentmen come do. toms		
'P" document	published prior to the international filing date but later than the	"&" document member of the same patent fa	milv		
priority date claimed					
Date of the actual completion of the international search Date of mailing of the international search report					
	05 (18.03.2005)	Q4 NOV 2000			
	ailing address of the ISA/US	Authorized officer			
	il Stop PCT, Attn: ISA/US	Cecilia Tsang (Octor SM)			
	nmissioner for Patents . Box 1450	Set ,			
Ala	xandria, Virginia 22313-1450	Telephone No. 703-308-1235	•		
Facsimile No	Facsimile No. (703) 305-3230				

International application No.

PCT/US04/23788

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)			
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:			
ı. 🗵	⅓	Claims Nos.: 43 because they relate to subject matter not required to be searched by this Authority, namely: in claim 43, although numbered as a claim, there is no subject matter being claim.	
2.		Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:	
3.	-	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).	
Box No	о. Ш	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)	
This Interpretation	ternat See C	ional Searching Authority found multiple inventions in this international application, as follows: ontinuation	
1. [2. [3. [As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of any additional fees. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:	
4. Remar	rk on	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-42 in part and 44-64 in part Protest The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee. The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation. No protest accompanied the payment of additional search fees.	

Form PCT/ISA/210 (continuation of first sheet(2)) (April 2005)

International application No. PCT/US04/23788

BOX III. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claims 1-42 in part and 44-64 in part, drawn to compounds, pharmaceutical composition comprising the same and methods of using the same wherein the variable X is methylene, the variable Y is oxygen and none of the variables R1-R6 and R13 and R14 is a heterocyclic moiety.

Group II, claims 1-42 in part and 44-64 in part, drawn to compounds, pharmaceutical composition comprising the same and methods of using the same wherein the variable X is methylene, the variable Y is oxygen and at least one of the variables R1-R6 and R13 and R14 is a heterocyclic moiety.

Group III, claims 1-42 in part and 44-64 in part, drawn to compounds, pharmaceutical composition comprising the same and methods of using the same wherein the variable X is methylene, the variable Y is sulfur and none of the variables R1-R6 and R13 and R14 is a heterocyclic moiety.

Group VI, claims 1-42 in part and 44-64 in part, drawn to compounds, pharmaceutical composition comprising the same and methods of using the same wherein the variable X is methylene, the variable Y is sulfur and at least one of the variables R1-R6 and R13 and R14 is a heterocyclic moiety.

Group V, claims 1-42 in part and 44-64 in part, drawn to compounds, pharmaceutical composition comprising the same and methods of using the same wherein the variable X is methylene, the variable Y is NR18 and at least one of the variables R1-R6 and R13 and R14 is a heterocyclic moiety.

Group VI, claims 1-42 in part and 44-64 in part, drawn to compounds, pharmaceutical composition comprising the same and methods of using the same wherein the variable X is methylene, the variable Y is NR18 and none of the variables R1-R6 and R13 and R14 is a heterocyclic moiety.

Group VII, claims 1-42 in part and 44-64 in part, drawn to compounds, pharmaceutical composition comprising the same and methods of using the same wherein the variable Y is methylene, the variable X is oxygen and none of the variables R1-R6 and R13 and R14 is not a heterocyclic moiety.

International application No. PCT/US04/23788

Group VIII, claims 1-42 in part and 44-64 in part, drawn to compounds, pharmaceutical composition comprising the same and methods of using the same wherein the variable Y is methylene, the variable X is oxygen and at least one of the variables R1-R6 and R13 and R14 is a heterocyclic molety.

Group XI, claims 1-42 in part and 44-64 in part, drawn to compounds, pharmaceutical composition comprising the same and methods of using the same wherein the variable Y is methylene, the variable X is sulfur and none of the variables R1-R6 and R13 and R14 is a heterocyclic moiety.

Group X, claims 1-42 in part and 44-64 in part, drawn to compounds, pharmaceutical composition comprising the same and methods of using the same wherein the variable Y is methylene, the variable X is sulfur and at least one of the variables R1-R6 and R13 and R14 is a heterocyclic moiety.

Group XI, claims 1-42 in part and 44-64 in part, drawn to compounds, pharmaceutical composition comprising the same and methods of using the same wherein the variable Y is methylene, the variable X is NR18 and none of the variables R1-R6 and R13 and R14 is a heterocyclic molety.

Group XII, claims 1-42 in part and 44-64 in part, drawn to compounds, pharmaceutical composition comprising the same and methods of using the same wherein the variable Y is methylene, the variable X is NR18 and at least one of the variables R1-R6 and R13 and R14 is a heterocyclic moiety.

Group XIII, claims 1-42 in part and 44-64 in part, drawn to compounds, pharmaceutical composition comprising the same and methods of using the same wherein the variables X and Y are not methylene, and none of the variables R1-R6 and R13 and R14 is a heterocyclic moiety.

Group XVI, claims 1-42 in part and 44-64 in part, drawn to compounds, pharmaceutical composition comprising the same and methods of using the same wherein the variables X and Y are not methylene and at least one of the variables R1-R6 and R13 and R14 is a heterocyclic moiety.

The inventions listed as Groups I-XIV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: In a Markush practice, wherein a single claim defines alternatives (chemical or nonchemicals) is governed by Rule 13.2, thus the requirement of a special technical feature are defined by:

(a) All alternatives have a common property or activity AND

(b)(1) a common structure is present, for instance a significant structural element is shared by all of the alternatives OR (b)(2) in cases where the common structure cannot be the unifying criteria all the alternatives belong to a recognized class of compounds to which the invention pertains.

The phrase "significant structural element" as refers above should constitutes a structurally distinctive portion of their structure in view of the prior art. In the instant case, compounds embraced by claims 1-21 do not share a common structure in view of the prior art because the common core of the instant claims, a benzene ring is already disclosed in the prior art in multiple references, see for instance Caplus accession number 1916:15613 abstract for Reverdin et al, Archives des Sciences Physiques et Naturelles (1916), 42, 47-53. Reverdin discloses 2,6-dinitro-N-phenyl benzylamine, having a registry number 744239-58-5. See also Aldrich, Handbook of Fine Chemicals and Laboratoty Equipment, 2000-2001, page 178 disclosing 2-(benzyloxy)phenol, registry number 6272-38-4; 4-(benzyloxy)phenol, registry number 1103-16-2 and page 179, disclosing benzyl phenyl sulfide, having registry number 831-91-4 and benzyl phenyl ether, having a registry number 946-80-5. All the cited compounds are disclosed by the prior art and all of them contain a benzene ring and even more they embraced the definition of having two benzene rings connected be the same variables groups X, Y as defined by claim 1.

Therefore compounds embraced by claims 1-21 are not link by a special technical feature because they do not share a common core that can be considered as part of Applicant's contribution to the art.